AI Article Synopsis
- This study explores a new scintillator dosimetry system designed for ultra-high dose rate (UHDR) radiotherapy, addressing the challenges faced by existing systems that struggle with high mean dose rates (above 100 Gy/s).
- Extensive testing showed that the system maintains consistent dose measurements and is unaffected by different dosing conditions within specified limits, allowing for precise monitoring of rapid pulses (up to 120 Hz).
- With proper calibration and adjustments, this innovative system offers reliable real-time feedback for dosimetry in UHDR applications, potentially enhancing techniques like FLASH-radiotherapy and expanding its use in the field.
Article Abstract
Background: Scintillation dosimetry has promising qualities for ultra-high dose rate (UHDR) radiotherapy (RT), but no system has shown compatibility with mean dose rates ( above 100 Gy/s and doses per pulse () exceeding 1.5 Gy typical of UHDR (FLASH)-RT. The aim of this study was to characterize a novel scintillator dosimetry system with the potential of accommodating UHDRs.
Methods And Materials: A thorough dosimetric characterization of the system was performed on an UHDR electron beamline. The system's response as a function of dose, , and the pulse dose rate was investigated, together with the system's dose sensitivity (signal per unit dose) as a function of dose history. The capabilities of the system for time-resolved dosimetric readout were also evaluated.
Results: Within a tolerance of ±3%, the system exhibited dose linearity and was independent of and within the tested ranges of 1.8-1341 Gy/s and 0.005-7.68 Gy, respectively. A 6% reduction in the signal per unit dose was observed as was increased from 8.9e4-1.8e6 Gy/s. Additionally, the dose delivered per integration window of the continuously sampling photodetector had to remain between 0.028 and 11.64 Gy to preserve a stable signal response per unit dose. The system accurately measured of individual pulses delivered at up to 120 Hz. The day-to-day variation of the signal per unit dose at a reference setup varied by up to ±13% but remained consistent (<±2%) within each day of measurements and showed no signal loss as a function of dose history.
Conclusions: With daily calibrations and specific correction factors, the system reliably provides real-time, millisecond-resolved dosimetric measurements of pulsed conventional and UHDR beams from typical electron linacs, marking an important advancement in UHDR dosimetry and offering diverse applications to FLASH-RT and related fields.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10942482 | PMC |
Publication Analysis
Top Keywords
Similar Publications
No definite associations between opioid doses and severity of acute pancreatitis - Results from a multicentre international prospective study.
Pancreatology
December 2024
HPB and Transplant Unit, Freeman Hospital, Newcastle upon Tyne, UK; Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, UK. Electronic address:
Background: Abdominal pain is the cardinal symptom of acute pancreatitis (AP), often requiring opioid therapy. This study aimed to investigate the dose-dependent relationship between opioid therapy and moderately severe or severe AP.
Methods: This was a post-hoc analysis of the prospective PAINAP database, which recruited patients with first-time AP from 118 centres across 27 countries between April-June 30, 2022.
Multicenter approach to predict plan quality of robotic intracranial SRS/SRT.
Phys Med
December 2024
IRCCS San Raffaele Scientific Institute, Medical Physics, Milano, Italy.
Purpose: This study analyzed inter-institute conformity and dose gradient variability of CyberKnife (CK) brain SRS/SRT plans. The feasibility of multi-center predictive models was investigated, aiming at guided/automated planning optimization.
Methods: Data from 335 clinical plans, delivered for single lesions in 1-5 fractions, were collected by 8 CK centers.
Individual and joint effects of exposure to multiple organophosphate esters and the risk of depression in adults: Differences in sex, age, and physical activity.
Ecotoxicol Environ Saf
December 2024
Department of Epidemiology, School of Public Health, Guangxi Medical University, Nanning, Guangxi 530021, China. Electronic address:
Depression, a severe mental disorder, is a prominent cause of global disability and worldwide. Organophosphate esters (OPEs) are neuron-disrupting chemicals that potentially cause depression. However, the effects of OPEs on depression remain unclear.
View Article and Find Full Text PDFClinical remission in patients with severe eosinophilic asthma treated with mepolizumab: A analysis of RELIght study.
Allergy Asthma Proc
January 2025
2nd Respiratory Department, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Remission of asthma can occur as part of the natural history of the disease; however, the use of biologics can result in disease remission in some patients. In this post hoc analysis of the RELIght study, we aimed to evaluate clinical remission in real life among patients treated with mepolizumab, to detect possible differences between "remitters" and "nonremitters," and to evaluate possible predictors of remission. Clinical remission was defined as the absence of asthma exacerbations, discontinuation of oral corticosteroids (OCS), achievement of asthma control (Asthma Control Test [ACT] ≥ 20), and stable or improved lung function.
View Article and Find Full Text PDFSuperior persistence of ustekinumab compared to anti-TNF in vedolizumab-experienced inflammatory bowel diseases patients: a real-world cohort study.
BMC Gastroenterol
December 2024
Department of Gastroenterology and Hepatology, Linkou Branch, Chang Gung Memorial Hospital, 5, Fu-Hsin Street, Guei-Shan District, Taoyuan, 33305, Taiwan.
Background/aims: The increasing use of biologic therapies for moderate to severe inflammatory bowel disease (IBD) highlights the importance of optimal treatment sequencing, particularly after vedolizumab (VDZ) exposure. Studies comparing the effectiveness of ustekinumab (UST) and antitumor necrosis factor (anti-TNF) agents post-VDZ are limited.
Methods: This retrospective study analyzed VDZ-experienced IBD patients treated with UST or anti-TNF (adalimumab and infliximab) from May 2019 to January 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!